Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Feb;67(2):374–378. doi: 10.1038/bjc.1993.68

Breast cancer prognosis is poor when total plasminogen activator activity is low.

J Yamashita 1, M Ogawa 1, K Inada 1, S Yamashita 1, Y Nakashima 1, T Saishoji 1, K Nomura 1
PMCID: PMC1968174  PMID: 8431369

Abstract

Plasminogen activator (PA) is a serine protease which exists in two forms: tissue-type (t-PA) and urokinase-type (u-PA). The total PA activity was measured in tumour extracts of 235 breast cancer patients who were followed for a median of 8.5 years after surgery. Patients were initially divided into three groups with low (< 60 units mg-1 protein), intermediate (60-300 unit mg-1 protein), or high (> 300 unit mg-1 protein) total PA activity in tumour extracts. The PA activity was not significantly associated with the recognised prognostic factors of age, menstrual status, tumour size, lymph node involvement, histologic type, grade of anaplasia, and/or vessel involvement. A significant association was found between total PA activity and the oestrogen receptor (ER) or progesterone receptor (PgR) status. Among receptor-positive tumours, a significantly greater proportion of patients had high PA activity in their tumour extracts. Breast cancer patients with low total PA activity had a significantly shorter disease-free and overall survival rate when compared to those with intermediate or high PA activity. In univariate and multivariate analyses, total PA activity (< 60 unit mg-1 vs > or = 60 unit mg-1 protein) was found to be a significant prognostic factor for disease-free and overall survival of about the same import as lymph node involvement. Furthermore, the combination of total PA activity and nodal status could be even more precise in predicting survival times and probabilities in individual patients. This retrospective study demonstrates the total PA activity is a valuable prognostic factor in determining prognosis in human breast cancer.

Full text

PDF
374

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Butler W. B., Berlinski P. J., Hillman R. M., Kelsey W. H., Toenniges M. M. Relation of in vitro properties to tumorigenicity for a series of sublines of the human breast cancer cell line MCF-7. Cancer Res. 1986 Dec;46(12 Pt 1):6339–6348. [PubMed] [Google Scholar]
  3. Colombi M., Rebessi L., Boiocchi M., Barlati S. Relationship between circulating plasminogen activators and tumor development in mice. Cancer Res. 1986 Nov;46(11):5748–5753. [PubMed] [Google Scholar]
  4. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  5. Dickerman H. W., Martinez H. L., Seeger J. I., Kumar S. A. Estrogen regulation of human breast cancer cell line MCF-7 tissue plasminogen activator. Endocrinology. 1989 Jul;125(1):492–500. doi: 10.1210/endo-125-1-492. [DOI] [PubMed] [Google Scholar]
  6. Duffy M. J. Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol. 1987 May;23(5):583–589. doi: 10.1016/0277-5379(87)90326-9. [DOI] [PubMed] [Google Scholar]
  7. Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer. 1988 Aug 1;62(3):531–533. doi: 10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  8. Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res. 1988 Mar 1;48(5):1348–1349. [PubMed] [Google Scholar]
  9. Duffy M. J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J. J., Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990 Nov 1;50(21):6827–6829. [PubMed] [Google Scholar]
  10. Evers J. L., Patel J., Madeja J. M., Schneider S. L., Hobika G. H., Camiolo S. M., Markus G. Plasminogen activator activity and composition in human breast cancer. Cancer Res. 1982 Jan;42(1):219–226. [PubMed] [Google Scholar]
  11. Foekens J. A., Portengen H., van Putten W. L., Peters H. A., Krijnen H. L., Alexieva-Figusch J., Klijn J. G. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res. 1989 Nov 1;49(21):5823–5828. [PubMed] [Google Scholar]
  12. Inada K., Yamashita J., Matsuo S., Nakashima Y., Yamashita S., Ogawa M. Hormone control of total plasminogen activator activity is specific to malignant DMBA-induced rat mammary tumours. Br J Cancer. 1992 Apr;65(4):578–582. doi: 10.1038/bjc.1992.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Inada K., Yamashita J., Yoshimura T., Matsuo S., Nakashima Y., Yamashita S., Misumi A., Ogawa M. Hormonal regulation of plasminogen activator and peroxidase activities in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors and the rat uterus. Jpn J Surg. 1991 Mar;21(2):249–252. doi: 10.1007/BF02470918. [DOI] [PubMed] [Google Scholar]
  14. Jänicke F., Schmitt M., Ulm K., Gössner W., Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet. 1989 Oct 28;2(8670):1049–1049. doi: 10.1016/s0140-6736(89)91070-2. [DOI] [PubMed] [Google Scholar]
  15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  16. McGuire W. L., De La Garza M., Chamness G. C. Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res. 1977 Mar;37(3):637–639. [PubMed] [Google Scholar]
  17. Mignatti P., Robbins E., Rifkin D. B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 1986 Nov 21;47(4):487–498. doi: 10.1016/0092-8674(86)90613-6. [DOI] [PubMed] [Google Scholar]
  18. Mira-y-Lopez R., Osborne M. P., DePalo A. J., Ossowski L. Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy. Int J Cancer. 1991 Apr 1;47(6):827–832. doi: 10.1002/ijc.2910470606. [DOI] [PubMed] [Google Scholar]
  19. Mizoguchi H., Uchiumi T., Ono M., Kohno K., Kuwano M. Enhanced production of tissue-type plasminogen activator by estradiol in a novel type variant of human breast cancer MCF-7 cell line. Biochim Biophys Acta. 1990 May 22;1052(3):475–482. doi: 10.1016/0167-4889(90)90158-a. [DOI] [PubMed] [Google Scholar]
  20. Orenstein N. S., Buczynski A., Dvorak H. F. Cryptic and active plasminogen activators secreted by line 10 tumor cells in culture. Cancer Res. 1983 Apr;43(4):1783–1789. [PubMed] [Google Scholar]
  21. Ossowski L., Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 1983 Dec;35(3 Pt 2):611–619. doi: 10.1016/0092-8674(83)90093-4. [DOI] [PubMed] [Google Scholar]
  22. Paranjpe M., Engel L., Young N., Liotta L. A. Activation of human breast carcinoma collagenase through plasminogen activator. Life Sci. 1980 Apr 14;26(15):1223–1231. doi: 10.1016/0024-3205(80)90067-3. [DOI] [PubMed] [Google Scholar]
  23. Persky B., Ostrowski L. E., Pagast P., Ahsan A., Schultz R. M. Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion. Cancer Res. 1986 Aug;46(8):4129–4134. [PubMed] [Google Scholar]
  24. Reich R., Thompson E. W., Iwamoto Y., Martin G. R., Deason J. R., Fuller G. C., Miskin R. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res. 1988 Jun 15;48(12):3307–3312. [PubMed] [Google Scholar]
  25. Sappino A. P., Busso N., Belin D., Vassalli J. D. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res. 1987 Aug 1;47(15):4043–4046. [PubMed] [Google Scholar]
  26. Sumiyoshi K., Baba S., Sakaguchi S., Urano T., Takada Y., Takada A. Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. Thromb Res. 1991 Jul 1;63(1):59–71. doi: 10.1016/0049-3848(91)90270-7. [DOI] [PubMed] [Google Scholar]
  27. Thorpe S. M., Rochefort H., Garcia M., Freiss G., Christensen I. J., Khalaf S., Paolucci F., Pau B., Rasmussen B. B., Rose C. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res. 1989 Nov 1;49(21):6008–6014. [PubMed] [Google Scholar]
  28. Uchiumi T., Mizoguchi H., Hagino Y., Kohno K., Kuwano M. Counteraction of estradiol-induced activation of tissue-type plasminogen activator in a human breast cancer cell line by an anti-estrogen, LY117018. Int J Cancer. 1991 Jan 2;47(1):80–85. doi: 10.1002/ijc.2910470115. [DOI] [PubMed] [Google Scholar]
  29. Yamashita J., Horiuchi S., Kimura M., Nishimura R., Akagi M. Plasminogen activator as a functional marker for estrogen dependence in human breast cancer cells. Jpn J Cancer Res. 1986 Feb;77(2):177–181. [PubMed] [Google Scholar]
  30. Yamashita J., Horiuchi S., Shigaki N., Fujino N., Akagi M. Estrogen-dependent plasminogen activator in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors in vivo and in vitro. Gan. 1984 Aug;75(8):681–689. [PubMed] [Google Scholar]
  31. Yamashita J., Inada K., Yamashita S., Matsuo S., Nakashima Y., Ogawa M. Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells. Horm Metab Res. 1992 Dec;24(12):565–569. doi: 10.1055/s-2007-1003391. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES